Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Leases: 2019-2025

Historic Operating Leases for Collegium Pharmaceutical (COLL) over the last 7 years, with Sep 2025 value amounting to $4.5 million.

  • Collegium Pharmaceutical's Operating Leases fell 23.89% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year decrease of 23.89%. This contributed to the annual value of $5.5 million for FY2024, which is 9.55% down from last year.
  • Per Collegium Pharmaceutical's latest filing, its Operating Leases stood at $4.5 million for Q3 2025, which was down 7.25% from $4.9 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Operating Leases' 5-year high stood at $8.6 million during Q1 2021, with a 5-year trough of $4.5 million in Q3 2025.
  • For the 3-year period, Collegium Pharmaceutical's Operating Leases averaged around $5.8 million, with its median value being $5.9 million (2024).
  • Data for Collegium Pharmaceutical's Operating Leases shows a maximum YoY dropped of 23.89% (in 2025) over the last 5 years.
  • Over the past 5 years, Collegium Pharmaceutical's Operating Leases (Quarterly) stood at $8.0 million in 2021, then dropped by 10.55% to $7.1 million in 2022, then dropped by 13.89% to $6.1 million in 2023, then dropped by 9.55% to $5.5 million in 2024, then dropped by 23.89% to $4.5 million in 2025.
  • Its Operating Leases stands at $4.5 million for Q3 2025, versus $4.9 million for Q2 2025 and $5.2 million for Q1 2025.